Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0025202 (
melanoma
)
69,561
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The retinoblastoma protein (pRb) pathway is critical in regulating the G1 phase of the cell cycle and it is frequently disrupted in human cancers. Components of the pRb pathway which are often altered in tumour progression include the INK4 cyclin-dependent kinase (CDK) inhibitors p16INK4a/
CDKN2A
and p15INK4b/CDKN2B, CDK4, D-type cyclins and pRb. Several of these components were studied in a series of cultured
melanoma
cell lines in order to determine the frequency and spectrum of genetic alterations and to define targets for potential gene transfer studies. Also studied were the p16INK4a alternate transcript (p14ARF) and the p21(waf1) CDK inhibitor. The majority of the
melanoma
cell lines tested (13 out of 17; 76%) carried mutated (two), deleted (nine) or silenced (two) p16(INK4a). CDK4 was mutated or overexpressed in two
melanoma
cell lines with homozygously deleted
CDKN2A
and CDKN2B genes. This suggests that the selective growth advantages afforded by
CDKN2A
inactivation and CDK4 insensitivity are distinct and may involve the mediation of other CDK inhibitors or CDKs.
Melanoma
Res 1999 Feb
PMID:Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. 1033 30
The
CDKN2A
gene encodes the cell cycle inhibitor p16/ INK4A, which is involved in familial cutaneous melanoma. We have studied five Swedish familial
melanoma
kindreds characterized by germline mutations in
CDKN2A
and dysplastic naevus syndrome (DNS). We found significant correlations between germline
CDKN2A
mutations and
melanoma
and between DNS phenotype and
melanoma
, respectively. There was also a correlation between mutation status and the presence of DNS. In
CDKN2A
mutation carriers, all cases of early-onset
melanoma
occurred in DNS individuals, and the mean age at
melanoma
diagnosis was significantly lower in individuals with DNS than in those without a confirmed DNS phenotype. In one family where the proband had a P48L mutation in
CDKN2A
exon 1, the DNS phenotype was studied in detail. In vitro binding experiments established that the P48L mutant protein does not bind to cdk4 or cdk6 and thus is functionally abnormal. Furthermore, we demonstrated loss of heterozygosity at markers on chromosome 9p flanking the
CDKN2A
locus in a primary
melanoma
and a metastasis from the proband. Our results are consistent with the hypothesis that germline
CDKN2A
mutations and DNS both contribute to the predisposition to
melanoma
and may lead to the development of early-onset
melanoma
when present in the same individual.
Melanoma
Res 1999 Feb
PMID:Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds. 1033 31
Excessive sun exposure and family history are strong risk factors for the development of cutaneous melanoma. Inherited susceptibility to this type of skin cancer could therefore result from constitutively impaired capacity to repair ultraviolet (UV)-induced DNA lesions. While a proportion of familial
melanoma
kindreds exhibit germline mutations in the cell cycle regulatory gene
CDKN2A
(p16INK4a) or its protein target, cyclin-dependent kinase 4 (CDK4), the biochemical basis of most familial
melanoma
is unknown. We have examined lymphoblastoid cell lines from
melanoma
-affected and unaffected individuals from large hereditary
melanoma
kindreds which are not attributable to
CDKN2A
or CDK4 gene mutation. These lines were tested for sensitivity of clonogenic growth to UV radiation and for their ability to repair transfected UV-damaged plasmid templates (host cell reactivation). Two of seven affected-unaffected pairs differed in colony survival after exposure to UVB radiation; however, no significant differences were observed in the host-cell reactivation assays. These results indicate that
melanoma
susceptibility genes other than
CDKN2A
and CDK4 do not impair net capacity to repair UV-induced DNA damage.
Melanoma
Res 1999 Apr
PMID:Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation. 1038 Sep 35
CDKN2A
appears to be the major
melanoma
susceptibility gene, and is also mutated/deleted in sporadic tumours of various types including
melanoma
. Thus far most approaches to assessing the functionality of mutations in this gene have used in vitro methods such as CDK4 binding and kinase inhibition assays, with sometimes disparate conclusions about functional significance of some variants between studies. We have used a
melanoma
cell line (MM96L) with no functional p16, as the basis for a "semi-in vivo" transfection-based assay for exogenous p16 functionality based on the growth parameters of the cells and the behaviour of variant proteins after transfection of different
CDKN2A
cDNAs. Colony counts performed on these transfectants revealed that all but the wild type, + 24 bp ad A148T variants have a diminished ability to inhibit cell growth. All other variants detected either constitutionally in familial
melanoma
patients (I49T, R87P, G101W and V126D) or somatically in melanomas (N71S, and P81L), appeared functionally impaired in this assay. This diminution of function was independent of CDK4 and CDK6 binding ability. Furthermore, the predominant localization of these variants within the cell was different from that of wt p16. This mislocalization may provide an explanation for their lack of function, or alternatively, it may also be an indicator that the cells are processing unstable, misfolded p16 proteins. This novel assay for assessment of functionality of p16 variants may better reflect the role of some of these mutations in vivo, and as such is a useful adjunct to other in vitro assays.
...
PMID:Functional reassessment of P16 variants using a transfection-based assay. 1038 68
Uveal
melanoma
is the most common primary intraocular malignancy, with an annual incidence of 6 per million. The environmental factors known to increase the risk of cutaneous melanoma appear to be less important in ocular melanoma and it is conceivable that host factors have a greater impact. The coexistence of ocular and cutaneous melanoma in some patients suggests a predisposition to both types and implicates mutations in the
CDKN2A
gene in a proportion of these cases. An association between ocular melanoma and breast and/or ovarian cancer has also been reported and recent studies of breast cancer families strongly implicate BRCA2 as a predisposition gene. Other more common genes predisposing to ocular melanoma may be of low penetrance. An example of a gene in this class is MC1R, which affects host response to ultraviolet radiation. Identification of genes conferring an increased risk of ocular melanoma should provide insights into the pathogenesis of this tumour. Furthermore, it offers an opportunity to identify individuals at a high risk who may benefit from targeted surveillance. At present the identification of such individuals is restricted to the small number belonging to BRCA2 families and those with the atypical mole syndrome.
...
PMID:Genetic predisposition to ocular melanoma. 1069 48
Mutation analysis of two genes involved in
melanoma
susceptibility (
CDKN2A
/p16(INK4a) and CDK4) was undertaken in 131 probands with a family history of
melanoma
. Screening of all three exons of
CDKN2A
and exon 2 of CDK4 by single-strand conformation polymorphism (SSCP) analysis and/or direct sequencing identified a total of 10 different
CDKN2A
germline mutations, including 6 not previously described in the germline. All but one has been previously proven to, or is likely to, affect the structure and function of p16(INK4a). The incidence of
CDKN2A
mutation was 8.4% (11/131), but was significantly higher in families with three or more cases of
melanoma
(10/66, 15.1%) than in those in which only two relatives were affected (1/65, 1.5%). The incidence of
CDKN2A
mutation was also higher in families with three or more cases of
melanoma
and at least one member with multiple primary melanomas (6/19, 31.6%) than in similar families without multiple primary melanomas (4/47, 8.5%). One novel CDK4 variant of uncertain significance was found in a kindred that also carries a
CDKN2A
mutation. Genes Chromosomes Cancer 25:339-348, 1999.
...
PMID:CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. 1039 27
The
CDKN2A
gene that encodes the cell cycle inhibitor p16 shows mutations in many but not all 9p21-linked
melanoma
families. Most Dutch
melanoma
families segregate for a unique founder mutation (p16-Leiden), encoding a truncated nonfunctional p16 protein. The highly variable risk for p16-Leiden carriers to develop
melanoma
suggests a role for other genetic and/or environmental factors. We hypothesized that a 9p21 gene other than
CDKN2A
may be relevant in the remaining 9p21-linked
melanoma
families without p16 mutations but may also act as a risk modifier in p16-Leiden carriers. Haplotype analysis for 9p21 was performed using microsatellite markers in six p16-Leiden families originating from a founder population. p16-Leiden carriers in two families shared an unexpectedly large founder haplotype ( approximately 20-cM) around
CDKN2A
, mostly in proximal direction.
Melanoma
-positive p16-Leiden carriers from these families showed this extensive proximal haplotype compared with
melanoma
-negative p16-Leiden carriers from the same families. Additional p16-Leiden families less heavily affected with
melanoma
showed shorter haplotypes sharing, excluding the region proximally of
CDKN2A
. The presence of a gene involved in
melanoma
susceptibility proximal of
CDKN2A
is corroborated by somatic deletions of 9p in tumors, which frequently do not include
CDKN2A
but a more proximal chromosomal area instead. Our results provide a candidate region for further gene mapping in p16-negative 9p21-linked
melanoma
families and guide the search for risk modifiers in
melanoma
development.
...
PMID:A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families. 1040 Sep 25
Important risk factors for
melanoma
are densely clustered melanocytic nevi (common moles) and mutations in the p16 (
CDKN2A
) gene. Nevi may be subclassified as raised or flat. In our sample, raised nevi were 27% of the total, and the two kinds had a correlation of.33. Correlations for total-nevus count (TNC) in 153 MZ and 199 DZ twin pairs were.94 and.60, respectively, which are compatible with a very-high degree of genetic determination. We hypothesized that some of the genetic variance might be due to variation in the p16 gene. Analysis of linkage to a highly polymorphic marker (D9S942), located close to p16, detected quantitative-trait-loci (QTL) effects accounting for 27% of variance in TNC, rising to 33% if flat but not raised moles were considered. Total heritability was higher for raised (.69) than for flat (.42) moles, but QTL linkage was 0 for raised moles, whereas it accounted for 80% of the heritability of flat moles; additionally, family environment accounted for only 15% of variance in raised versus 46% in flat moles. These findings suggest that raised and flat nevi have very different etiologies. Longer alleles at D9S942 were associated with higher flat-mole counts, and a novel modification to a within-sibship association test showed that this association is genuine and not due to population stratification, although it accounts for only 1% of total variance. Since germline mutations in the exons of
CDKN2A
are rare, it is likely that variants in the noncoding regions of this gene, or in another gene nearby, are responsible for this major determinant of moliness and, hence, of
melanoma
risk.
...
PMID:A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. 1041 91
There are numerous risk factors for the development of malignant melanomas. Genetic and environmental aspects have to be considered. The most important genetic risk factor is a mutation in the
CDKN2A
gene, which is a turmorsuppressor-gene which regulates the cell cycle. In addition, the familial dysplastic nevus syndrome shows a marked risk for the development of
malignant melanoma
. Patients with xeroderma pigmentosum have an inability to repair UV-induced DNA defects. This constellation leads to early development of epitheliomas and malignant melanomas. Constitutional risk factors are fair-red hair and blue eyes with a high tendency for sunburns. The most important environmental factor is UV-exposition. Sunburns before the age of 15 and the total cumulative UV-dosage are high impact risk factors. The most important preventive measures are to check the whole skin at a regular base in a patient with the familal dysplastic nevus syndrome and in addition all persons should wear a hat, trousers, shirt and glasses. Furthermore direct sun exposure should be avoided during noon time.
...
PMID:[Risk factors for the development of malignant melanomas]. 1042 Aug 10
Eighteen human congenital melanocytic naevi (CMN) from 17 patients were screened for activating point mutations in the oncogenes N-ras and CDK4 and for sequence variants in the MC1R gene by combined RFLP-PCR/SSCP analysis. In addition, all lesions were screened for deletions and point mutations in the tumour suppressor genes p53 and p16INK4a (
CDKN2A
) by combined multiplex PCR/SSCP analysis. Positive screening data were specified by sequencing of the corresponding PCR product. Activating point mutations in the N-ras gene (nine CAA (Gln) to AAA (Lys) transversions and one CAA (Gln) to CGA (Arg) transition at codon 61) were detected at high frequency (56%). Furthermore, three missense mutations (V92M) and two silent mutations (CGA (Arg) to CGG (Arg), codon 213, exon 6) were found in the MC1R and p53 genes, respectively. No mutations were found in p16 or CDK4. The activated N-ras oncogene, which is also found in human cutaneous melanomas, may constitute a potential risk factor for
melanoma
formation within CMN.
...
PMID:Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. 1046 11
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>